The biopsy analysis of 93 melanoma patients proved that the higher the frequency and maturity of TA-HEC, the better the survival rate of patients receiving the combination of anti-PD-1 antibody and anti-CTLA-4 antibody[131]. The gene discussed is PDCD1; the disease is melanoma.